EUVIMEDEUVIMED entdecken
Crossref

Letter to the Editor: Toward biology-driven transplant oncology: The role of PIVKA-II in alpha-fetoprotein-normal hepatocellular carcinoma

Sagar Raut, Pradeep Naik E

World Journal of Gastrointestinal Oncology · 15.08.2026 · 18 (8)

DOI: 10.4251/wjgo.118170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 15.08.2026. Verfasst von Sagar Raut und 1 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver transplantation is the most effective therapy for selected patients with hepatocellular carcinoma (HCC). However, post-transplant recurrence limits long-term survival. Current transplant selection guidelines predominantly rely on morphological criteria, such as the Milan criteria. These criteria incompletely capture the biological heterogeneity of HCC. This limitation is particularly evident in HCC in which alpha-fetoprotein (AFP) levels are normal, leading to clinically occult aggressive tumor biology. This invited letter to the editor examines the clinical implications of the recent study published in the World Journal of Gastrointestinal Oncology by Abbas et al in which they identified PIVKA-II as a marker of aggressive tumor behavior in AFP-normal HCC. The elevated PIVKA-II levels were strongly associated with adverse biological features, including disease beyond the Milan criteria and portal vein tumor thrombosis despite normal AFP levels. PIVKA-II successfully stratified patients with a high likelihood of aggressive disease even when conventional imaging criteria were met. The framework for transplant oncology is constantly evolving, and we highlight that PIVKA-II may complement existing morphologic and biomarker-based selection models. We particularly emphasize the potential role of PIVKA-II in refining transplant eligibility, guiding downstaging strategies, and improving surveillance and waitlist management in patients with normal AFP levels. While prospective validation is required, incorporation of PIVKA-II for transplant evaluation represents a meaningful step toward biology-driven, precision-based allocation in HCC management.

Zitieren

APA

Raut, S., & E, P. N. (2026). Letter to the Editor: Toward biology-driven transplant oncology: The role of PIVKA-II in alpha-fetoprotein-normal hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 18(8). https://doi.org/10.4251/wjgo.118170

Vancouver

Raut S, E PN. Letter to the Editor: Toward biology-driven transplant oncology: The role of PIVKA-II in alpha-fetoprotein-normal hepatocellular carcinoma. World Journal of Gastrointestinal Oncology. 2026;18(8). doi:10.4251/wjgo.118170

BibTeX
@article{Raut2026,
  author = {Raut, Sagar and E, Pradeep Naik},
  title = {Letter to the Editor: Toward biology-driven transplant oncology: The role of PIVKA-II in alpha-fetoprotein-normal hepatocellular carcinoma},
  journal = {World Journal of Gastrointestinal Oncology},
  year = {2026},
  volume = {18},
  number = {8},
  doi = {10.4251/wjgo.118170}
}
Kostenlos starten →